Diltiazem Hydrochloride Injection — FDA Drug Shortage

To Be Discontinued — Hospira, Inc., A Pfizer Company

The FDA lists a drug shortage record for Diltiazem Hydrochloride Injection (injection) from Hospira, Inc., A Pfizer Company with status To Be Discontinued. The shortage was first posted on Jan 5, 2026.

Shortage details

Status
To Be Discontinued
Company
Hospira, Inc., A Pfizer Company
Package NDC
0409-4350-03
Dosage Form
Injection
Presentation
Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-4350-03)
Initial Posting
Jan 5, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.